insights_auto
Why is HALO up 13.02%?
Dive Deeperchevron_right
HALO:BMV
Halozyme Therapeutics, Inc.
MX$2,225.00
arrow_upward
+13.02%(+256.31) 1D
Oct 15, 10:56:30 AM GMT-6 · MXN
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
MX$2,225.00
High
MX$2,225.00
Low
MX$2,225.00
Mkt. cap
13.76B
Avg. vol.
440.00
Volume
50.00
52-wk high
MX$2,225.00
52-wk low
MX$1,126.00
No. of employees
423
Open
MX$2,225.00
High
MX$2,225.00
Low
MX$2,225.00
Mkt. cap
13.76B
Avg. vol.
440.00
Volume
50.00
52-wk high
MX$2,225.00
52-wk low
MX$1,126.00
No. of employees
423
News stories
From web sources and news partners
CNBC
·
44 minutes ago
Inside Edge’s Todd Gordon: Halozyme Therapeutics are beating estimates; raised full-year guidance
Yahoo Finance
·
8 hours ago
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
StocksToTrade
·
22 hours ago
HALO Stock Climbs As Patent Win And Deals Lift Outlook
Timothy Sykes
·
22 hours ago
HALO Stock Climbs As Dutch Court Injunction Lifts Bullish Bets
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com